Nuvectis Pharma, Inc. (NVCT)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 02:30PM EDT. Market open.
| Previous close | 7.10 |
| Open | 7.09 |
| Bid | 6.77 x 100 |
| Ask | 6.99 x 100 |
| Day's range | 6.62 - 7.39 |
| 52-week range | 6.20 - 18.65 |
| Volume | |
| Avg. volume | 95,374 |
| Market cap | 121.006M |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.43 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.00 |
Simply Wall St.Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
GlobeNewswireNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant to Alectinib, the Active Ingredient in AlecensaTM Fort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity
- Simply Wall St.
Insider Buys Additional US$51k In Nuvectis Pharma Stock
Whilst it may not be a huge deal, we thought it was good to see that the Nuvectis Pharma, Inc. ( NASDAQ:NVCT...
© 2024 Yahoo. All rights reserved.